IVERMECTIN AS ADJUVANT TO HYDROXYCHOLOROQUINE IN PATIENTS RESISTANT TO STANDARD TREATMENT FOR SARS-CoV-2: RESULTS OF AN OPEN-LABEL RANDOMIZED CLINICAL STUDY
Naveen Kishoria, Shuchi Mathur, Veeram Parmar, Rimple Jeet Kaur, Harish Agarwal, Bhawani Shankar Parihar, Somil Verma
Abstract
A cluster of pneumonia cases of unknown etiology was reported from the city of Wuhan, in the Hubei province of China, in December 2019. A novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the causative agent of the disease which was subsequently termed as the coronavirus disease (COVID-19) by the World Health Organization (WHO). SARS-CoV-2 mainly affects the lower res-piratory tract and manifests as pneumonia in humans.
Topics & Concepts
PneumoniaCoronavirusMedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)EtiologyDiseaseIvermectin2019-20 coronavirus outbreakAtypical pneumoniaVirologyOutbreakInternal medicineInfectious disease (medical specialty)Veterinary medicineCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchRespiratory viral infections research